Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients.
In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics can not only cure COVID-19 but also protect from infection. New fast-track antibody drug programmes have achieved unprecedented timelines from discovery to the clinics and give hope to save lives and cure COVID-19.
Polyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin.
Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its unique mechanism of action, asunercept may reduce lymphopenia, lung epithelial damage, and inflammatory cell death in COVID-19 patients, thus providing a unique therapeutic approach for this devastating disease.
12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and developments.
The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective treatments for a wide range of conditions. The improved use of data and the development of advanced AI-based technologies enable the fast and effective identification of drugs, accelerating drug discovery, repurposing and innovation.
Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate with experienced technology providers. Such partners can provide critical support from development through manufacturing, helping to eliminate bottlenecks and accelerating production of urgently needed vaccines.
More than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off.
As investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing.
After BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%.